Chi Podcasts

Dr. William Hallett outlines what he considers some of the greatest obstacles to assess immunogenicity of biologics. He also comments on the reason behind the new requirement for lower cut-point in assays, how to accelerate Biobetters to the market in the world of Biosimilars, and advice for the industry in biologic development to accelerate FDA approval. For more information, please visit http://www.PEGSummit.com/Immunogenicity/

An interview with the 2018 Young Scientist Keynote, Dr. Kipp Weiskopf. Insights into new exciting developments in the growing field of cancer immunotherapy, perspectives on where this field is heading, and trends shaping the next generation of cancer immunotherapy. For more details, please visit: http://www.PEGSummit.com/Plenary-Keynote/

Débora Araujo of Boehringer Ingelheim spoke to CHI to discuss her expertise in clinical trial agreements and some of the daily challenges she faces in negotiations and contracts. She specifically discusses some of the key barriers within and beyond the legal language of CTAs and also shares highlights from her forthcoming book, The Four Villains of Clinical Trial Agreement Delays and How to Defeat Them. Débora is speaking at the Clinical Trial Forecasting, Budgeting and Contracting conference, part of SCOPE Summit, taking place February 12-15, 2018 in Orlando, FL. For more details, please visit: http://www.SCOPESummit.com

Dr. Wells, Professor of Pharmaceutical Chemistry at the University of California, San Francisco, shares insights about his upcoming and the keynote presentation in the Emerging Technologies for Antibody Discovery conference being held on January 11th and 12th at PepTalk. For more information, please visit http://www.CHI-PepTalk.com/Antibody-Discovery/

In this podcast from CHI on September 20, 2017, Stephen Carey speaks about Omniox’s quest to deliver oxygen into the tumor microenvironment to improve immunotherapy response. He also remarks on the challenges facing tumor microenvironment research and strategies to overcome them. To see him in person, check out the Targeting the Tumor Microenvironment conference, part of ImPACT: Immunotherapy Progress and Clinical Treatments this December 5-7, 2017 in San Diego, CA. For more information, please visit http://www.ImPACTImmunotherapy.com/Tumor-Microenvironment/

Real World Evidence (RWE) is today’s big data challenge in Life Sciences. Medical records, registries, consultation reports, insurance claims, pharmacy data, social media, and patient surveys all contain valuable insights that Life Sciences organizations need to ascertain and prove the safety, efficacy and value of their drugs and medical devices. Join us to learn from our expert panelists as they discuss how Pharmaceutical and Medical Device Manufacturers are accelerating the development of RWE with a metadata-driven, semantically-enriched approach that enables them to: • Unify, harmonize and ensure governance of information from diverse data sources • Transform data into evidence that proves product efficacy and safety • Identify data patterns, connections, and relationships for faster time to insight For more information please visit http://www.Bio-ITWorld.com

In this podcast from CHI on September, Vancheswaran Gopalakrishnan and Jennifer Wargo speak about their work at the MD Anderson Cancer Center to understand the role of the microbiome in melanoma therapies, and the challenges that microbiome researchers are facing as this emerging field continues to move forward. To see him in person, check out the Microboime in Cancer Immunotherapy conference, part of ImPACT: Immunotherapy Progress and Clinical Treatments this December 5-7, 2017 in San Diego, CA. For more information, please visit http://www.ImPACTImmunotherapy.com/Microbiome-Immunotherapy/

Dr. Neeta Vora of University of North Carolina Chapel Hill spoke to CHI to discuss new opportunities and challenges in fetal whole exome sequencing for prenatal diagnosis. She discusses technical challenges, issues surrounding patient counseling, the potential for performing exome sequencing on noninvasively obtained samples, and her current research. Dr. Vora is speaking at the Advances in Prenatal Molecular Diagnostics conference, taking place November 28-29, 2017 in Cambridge, MA. For details, visit: http://www.Healthtech.com/Prenatal-Diagnostics/

This podcast highlights the Plenary Keynote presentation that John Lambert will be giving at PEGS Europe, 13 November 2018 in Lisbon, Portugal. Dr. Lambert discusses the difficulties of bringing novel constructs to market; advice for people introducing new ADC products in the clinical setting; and some of the most exciting new developments and emerging applications for ADCs. He shares his thoughts on ADCs that target both cancer initiating cells and differentiated cancer cells and clinical results; escape mechanisms tumor cells use to avoid destruction by ADCs; how perception shifted over the last three –four years on ADCs; and how can ADCs be combined with immuno-oncology approaches.

Tauseef Butt, CEO of Progenra Inc. speaks to CHI on September 8, 2017. Dr. Butt will be presenting during Immunomodulatory Small Molecules and Targeting the Ubiquitin Proteasome System, taking place this September 27-28 at Discovery on Target in Boston, MA. Topics include the benefits and challenges of immunomodulatory small molecules, Ubiquitin Protease (USP7) Inhibitors performance in animal models, Progenra’s discovery platform and their plans for developing other immunomodulatory strategies.

Dan Peer of Tel Aviv University speaks to CHI on September 8, 2017. Prof. Peer will be speaking during Emerging Oligonucleotide Therapeutics, taking place this September 27-28 at Discovery on Target in Boston, MA. Topics include how to deliver RNA molecules into specific target tissues, especially leukocytes, via systemic administration, working with RNA, CRISPR-based gene editing and clinical applications for Lipid-Based Nanoparticles and Extracellular Vesicles.

CHI interviews Dr. Craig Crews, Professor of Molecular, Cellular and Developmental Biology, Chemistry and Pharmacology at Yale University. Dr. Crews tells the story of the birth and evolution of PROTACs, provides commentary on preclinical challenges, and provides his outlook for continued development. Discussion and Questions Include: • The ability to target components of the Ubiquitin Proteasome System with bifunctional PROTACs molecules has recently generated significant interest within the drug discovery community. Can you share with us a bit about the history and progression of this new mode of drug action? • There are several commercial entities currently working on a new generation of bifunctional molecules, including Arvinas, a biotech you’ve founded. Can you discuss some of the current challenges surrounding this approach during pre-clinical development? • You are chairing a session and giving a keynote address during the upcoming Targeting the Ubiquitin Proteasome System conference, September 26

Avni Santani of CHOP speaks to CHI on Tuesday August 1st, 2018. Dr. Santani will be speaking during the Clinical NGS Assays: Applications and Interpretation meeting at the Next Generation Diangostics SummitAugust 15-18, in Washington DC. Topics include using a CHOP strategies for integrating NGS into clinical care, what challenges they have run into and new applications of NGS For more information, please visit http://www.NextGenerationDx.com/ngs-diagnostics

Danny Wells speaks to CHI on July 6th, 2017. Dr. Wells will be speaking during Neoantigen-Based Personalized Immunotherapies meeting at ImPACT: Immunotherapy Progress and Clinical Treatments, December 5-7th, 2018 in San Diego, California. Topics include scaling up personalized therapies, future clinical applications of neoantigens, and new frontiers in cancer immunotherapy. For more information, please visit http://www.ImpactImmunotherapy.com/Neoantigen-Immunotherapy/

Kerry R. Wiles of Vanderbilt University speaks to Cambridge Healthtech Institute on July 11, 2017. Her institution will be co-hosting and she herself will be a presenter and short course instructor during the Leaders in Biobanking Congress, October 25-27 in Nashville, Tennessee. Topics Include: Building the Cooperative Human Tissue Network with Lean Six Sigma principles to improve processes, how shifts in clinical care and surgical care affect biorepositories and scientists, and what it takes to sustain a biobank. For more information, please visit http://BiobankingCongress.com/Agenda#Day3 and http://BiobankingCongress.com/Short-Courses

Sarah Gray of the American Association of Tissue Banks speaks to Cambridge Healthtech Institute on July 7, 2017. She will be a presenter and short course instructor during the Leaders in Biobanking Congress, October 25-27 in Nashville, Tennessee. Topics Include: Expectations about the process of donating post-mortem tissue for biospecimen research, possible process improvements to better serve patients, and connecting researchers with donor families to build biobank credibility and enable public support of biospecimen donation for biomedical research. For more information, please visit http://www.BiobankingCongress.com/Agenda/ and http://www.BiobankingCongress.com/Short-Courses/

Dr. Elena Grigorenko of Diatherix, speaks to CHI on Wed. July 19, 2017. Dr. Grigorenko will be speaking during the Molecular Diagnostics for Infectious Disease Conference August 16-17, 2017 at the Grand Hyatt Washington in Washington, DC

Dr. Allen Northrup from MIODx recently spoke with CHI about the future applications of point-of-care in treating cancer. He will be speaking at the Next-Generation Dx Summit in the Enabling Point-of-Care Diagnostics conference on August 15. He is working on developments to predict and monitor patients’ responses to immunotherapy. For more information, please visit http://www.NextGenerationDx.com/Point-of-Care-Diagnostics/

Andrew Ko from UCSF recently spoke with CHI about his collaboration with Two Pore Guys, and the innovations they are implementing using point-of-care devices in liquid biopsy. He will be speaking at the Next-Generation Dx Summit in the Enabling Point-of-Care Diagnostics conference on August 15. Dr. Ko is working with Two Pore Guys advancing technology to enable cancer patients to monitor their progress from home. For more information, please visit http://www.NextGenerationDx.com/Point-of-Care-Diagnostics/

Michael Messenger and Alison Smith from the University of Leeds recently sat down with CHI to discuss their poster “Early cost effectiveness and value of information analysis to accelerate diagnostic test research and development - a case study in acute kidney injury” which won the Symposia Poster Award at the Molecular Medicine Tri Conference this year. They describe their process of developing new diagnostic tests which considers both clinical utility and economic cost effectiveness. They also speak about what drew them to the Tri Conference this year and the connections that they were able to make with potential partnering companies. For more information, please visit http://http://www.TriConference.com/Student-Fellowship/